Myelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and management
|
Jul 2012
|
Am J Hematol
|
myelodysplastic syndromes (MDS)
|
Prediction of adverse events during Intensive Induction chemotherapy for acute myeloid leukemia or high-grade myelodysplastic syndromes
|
Jan 2014
|
Am J Hematol
|
myelodysplastic syndromes (MDS)
|
Phase II clinical study of erlotinib for treatment of myelodysplastic syndromes
|
Apr 2014
|
Am J Hematol
|
myelodysplastic syndromes (MDS)
|
Effect of race on outcomes after allogeneic hematopoietic cell transplantation for severe aplastic anemia.
|
Oct 2013
|
Am J Hematol
|
aplastic anemia
|
IDH mutations are closely associated with mutations of DNMT3A, ASXL1 and SRSF2 in patients with myelodysplastic syndromes and are stable during disease evolution.
|
Oct 2013
|
Am J Hematol
|
myelodysplastic syndromes (MDS)
|
Evaluation of revised IPSS cytogenetic risk stratification and prognostic impact of monosomal karyotype in 783 patients with primary myelodysplastic syndromes.
|
May 2013
|
Am J Hematol
|
myelodysplastic syndromes (MDS)
|
Clinical Outcomes in Adult Patients with Aplastic Anemia- a single institution experience
|
Aug 2017
|
Am J Hematol
|
aplastic anemia
|
Myelodysplastic syndromes: Contemporary review and how we treat
|
Jan 2016
|
Am J Hematol
|
myelodysplastic syndromes (MDS)
|
Impact of Achievement of Complete Cytogenetic Response on Outcome in Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agents
|
Jan 2017
|
Am J Hematol
|
myelodysplastic syndromes (MDS)
|
Calculator-free point-of-care prognostication in myelodysplastic syndromes.
|
Jan 2019
|
Am J Hematol
|
myelodysplastic syndromes (MDS)
|